This inventor holds 5 USPTO granted patents, plus 2 CIPO patents and 3 EPO patents. Top assignees: Riken Corporation, Sumitomo Chemical Company, Limited, Sumitomo Dainippon Pharma Co., Ltd.. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 889 
2 out of 6,960 
2 out of 110 Years Active: 2022-2025
Title: Yasushi Hiramine: Innovator in Retinal Tissue Production
Introduction
Yasushi Hiramine is a prominent inventor based in Kobe, Japan. He has made significant contributions to the field of biomedical engineering, particularly in the production of retinal tissue. With a total of 5 patents to his name, Hiramine's work has the potential to impact the treatment of various eye-related conditions.
Latest Patents
Hiramine's latest patents include a production method for retinal tissue. This innovative method involves several steps aimed at producing retinal cells or retinal tissue. Additionally, he has developed an agent for removing undifferentiated iPS cells. This compound has a specific formula that includes various chemical components, which are designed to inhibit the sphere-forming ability of cancer cells, making it useful in the removal of iPS cells.
Career Highlights
Throughout his career, Yasushi Hiramine has worked with notable organizations such as Riken Corporation and Sumitomo Dainippon Pharma Co., Ltd. His experience in these companies has allowed him to refine his skills and contribute to groundbreaking research in his field.
Collaborations
Hiramine has collaborated with esteemed colleagues, including Atsushi Kuwahara and Suguru Yamasaki. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Yasushi Hiramine is a distinguished inventor whose work in retinal tissue production and iPS cell removal showcases his commitment to advancing medical science. His contributions are paving the way for future innovations in the treatment of eye diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile